Korea Research Institute of Chemical Technology

Hanall Biopharma Co., Ltd.

Korea Research Institute of Bioscience and Biotechnology

Cj Corporation

Jeil Pharm. Co., Ltd.

Hyae Gyeong Cheon

Sang Dal Rhee

Won Hoon Jung

Sung Soo Jun

Kwang-Rok Kim

Sung Wuk Kim

Sung-eun Yoo

Sung Soo Kim

Jong Cheol Lee

Jeong-Hyung Lee

Seung Jun Kim

Jae Mok Lee

Jin Hee Ahn

Seung Kyu Kang

Jong Min Kim

Sung Dae Park

Sung-Don Yang

Young Sik Cho

Kwang Rok Kim

Nam Gee Kim

Kyu Yang Yi

Jee Hee Suh

Hyoung Rae Kim

Byung Ho Lee

Jae Yang Kong

Dong Ju Jeon

Young Gwan Jo

Jong-Cheol Lee

Ge Hyeong Lee

Kwang-Seok Oh

Jung Ki Kim

Seog Beom Song

Jong Hwan Song

Nack Jeong Kim

Myung Ae Bae

Sung Eun Yoo

Jin Sook Song

Mija Ahn

Hye Jung Kang

Jaesung No

Sun Mee Kim

Min Jung Seo

Byung Cheol Shin

Jang Hyuk Lee

Soon Ji Kwon

Bum Suk Son

Bo Gan Song

Sun Chul Huh

Koun Ho Lee

Kil Woong Mo

Chang Min Park

Ikyon Kim

Gehyeong Lee

Zaesung No

Aeri Lee

Hasoo Seong

The present invention relates to a composition for external application for improving a skin disease (e.g. psoriasis). The composition contains adenosylcobalamin (coenzyme B12), optionally in admixture with other cobalamins. The composition can be present in the form of liposomal preparations, which are made of a phospholipid and cholesterol.

Compositions for external application, containing adenosylcobalamin for improvement of skin diseases

Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.

1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same

The present invention provides an N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.

N1-2-thiophene-2-ylethyl-N2-substituted biguanide derivate, preparation method thereof, and pharmaceutical composition containing the same as active ingredients

The present invention provides an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.

N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative, preparation method thereof, and pharmaceutical composition containing same

The present invention is directed to a novel imidazole derivative having an aryl piperidine substituent of formula (I) and a method for preparation thereof, and a pharmaceutical composition containing said imidazole derivative as an active ingredient for preventing or treating a MCH (melanine-concentrating hormone)-related disease.

Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same

The present invention relates to novel {7-(3',4&#x2032;-dialkoxyphenyl)-[1,2,4]-triazolo[1,5-a]pyrimidine compounds or pharmaceutically acceptable salts thereof, a process for preparing the same, and pharmaceutical compositions for treating or preventing inflammatory diseases including asthma and chronic obstructive pulmonary disease, arthritis, atopic dermatitis, cancers including leukemia, and degenerative brain diseases including Alzheimer's disease, depression and memory impairment, which comprises the same as an active ingredient.

7-(3',4&#x2032;-Dialkoxyphenyl)[1,2,4]-triazolo[1,5-A]pyrimidine compounds, process for preparing thereof, and pharmaceutical composition for treating or preventing asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases comprising the same

The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.

Indene derivatives and process for the preparation thereof

An indene derivative for selectively modulating the activities of peroxisome proliferator activated receptors (PPARs) having the following formula (I): wherein, or phenyl; being each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, CN, NH, NO, OR, phenyloxy, Calkyl, and Ccycloalkyl; and

The present invention relates to a 5-(1,3-diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine-2,4-dione derivative or its pharmaceutically acceptable salts thereof, a method for preparing the same and an anticancer agent composition comprising the same as an active ingredient.

5-(1,3-Diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine,2,4-dione derivatives useful as anticancer agent

Growing community of inventors

Daejeon, South Korea

Hyae Gyeong Cheon